The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta‐analysis-Reference-Cited by-同舟云学术

The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta‐analysis

Published:2023-02-24 Issue:6 Volume:110 Page:774-777
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Molica Stefano¹,Allsup David¹²,Polliack Aaron³,Giannarelli Diana⁴

Affiliation:

1. Department Haematology Hull University Teaching Hospitals NHS Trust Hull UK

2. Centre for Biomedicine Hull York Medical School Hull UK

3. Hadassah University Hospital and Hebrew University Medical School Jerusalem Israel

4. Biostatistics Unit, Scientific Directorate Fondazione Policlinico Universitario A. Gemelli, IRCCS Rome Italy

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13943

Reference21 articles.

1. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures

2. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022

4. Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves

5. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety profile of first-line targeted therapies in elderly and/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2024-09

2. Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints;Expert Review of Hematology;2024-06-13

3. Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy;Expert Review of Hematology;2023-10-16